Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia

Blood

Volumn 107, Issue 4, 2006, Pages 1570-1581

  Ge, Yubin ^b   Dombkowski, Alan A ^b   LaFiura, Katherine M ^b   Tatman, Dana ^b   Yedidi, Ravikiran S ^b   Stout, Mark L ^b   Buck, Steven A ^b   Massey, Gita ^b   Becton, David L ^b   Weinstein, Howard J ^b   Ravindranath, Yaddanapudi ^b   Matherly, Larry H ^b   Taub, Jeffrey W ^a  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BONE MARROW STROMAL CELL ANTIGEN 2; CELL ANTIGEN; CYTARABINE; GLYCOPROTEIN; MEMBRANE PROTEIN; TRANSCRIPTION FACTOR GATA 1; UNCLASSIFIED DRUG;

ACUTE MEGAKARYOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL SURVIVAL; CHEMOTHERAPY; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DIFFERENTIAL DISPLAY; DOWN SYNDROME; GENE ACTIVATION; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; SAMPLE; SENSITIVITY ANALYSIS; SOMATIC MUTATION; STROMA CELL; SURVIVAL RATE; TRANSACTIVATION; UNINDEXED SEQUENCE; VALIDATION PROCESS; X CHROMOSOME LINKED DISORDER;

EID: 32644453700     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2219     Document Type: Article

References (32)

1. Taub JW. Relationship of chromosome 21 and acute leukemia in children with Down syndrome. J Pediatr Hematol Oncol. 2001;23:175-178.
2. Athale UH, Razzouk BI, Raimondi SC, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood. 2001;97:3727-3732.
3. Lange BJ, Kobrinsky N, Barnard DR, et al. Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891. Blood. 1998;91:608-615.
4. Zipursky A, Thorner P, De Harven E, Christensen H, Doyle J. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res. 1994;18:163-171.
5. Ravindranath Y, Abella E, Krischer J, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML study 8498. Blood. 1992;80:2210-2214.
6. Ravindranath Y, Yeager AM, Chang MN, et al. Acute myeloid leukemia in children: a randomized comparative study of purged autologous bone marrow transplantation versus intensive multiagent consolidation chemotherapy in first remission (Pediatric Oncology Group Study-POG 8821). N Engl J Med. 1996;334:1428-1434.
7. Gamis AS, Woods WG, Alonzo TA, et al. Children's Cancer Group Study 2891. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891. J Clin Oncol. 2003;21:3415-3422.
8. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia. 2005;19:1355-1360.
9. Zeller B, Gustafsson G, Forestier E, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol. 2005;128:797-804.
10. Kojima S, Sako M, Kato K, et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia. 2000;14:786-791.
11. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-152.
12. Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101:4298-4300.
13. Hitzler JK, Cheung J, Li Y, et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood. 2003;101:4301-4304.
14. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102:981-986.
15. Harigae H, Xu G, Sugawara T, Ishikawa I, Toki T, Ito E. The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome. Blood. 2004;103:3242-3243.
16. Taub JW, Ge Y. Down Syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer. 2005;44:33-39.
17. Ge Y, Jensen TL, Stout ML, et al. The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res 2004;64:728-735.
18. Ge Y, Stout ML, Tatman DA, et al. GATA1, cytidine deaminase and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst. 2005;97:226-231.
19. Taub JW, Huang X, Matherly LH, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood. 1999;94:1393-1400.
20. Ge Y, Jensen TL, Matherly LH, Taub JW. Transcriptional regulation of the cystathionine-β-synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. Blood. 2003;101:1551-1557.
21. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B Met. 1995;57:289-300.
22. Ishikawa J, Kaisho T, Tomizawa H, et al. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics. 1995;26:527-534.
23. Ohtomo T, Sugamata Y, Ozaki Y, et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun. 1999;258:583-591.
24. Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol. 2001;29:448-457.
25. Konopleva M, Konoplew S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia. 2002;16:1713-1724.
26. Zweegman S, Veenhof MA, Debili N, Schuurhuis GJ, Huijgens PC, Drager AM. Megakaryocytic differentiation of human progenitor cells is negatively influenced by direct contact with stroma. Leukemia. 1999;13:935-943.
27. Ross ME, Mahfouz R, Onciu M, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood. 2004;104:3679-3687.
28. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350:1617-1628.
29. Daniel CP, Ponting IL, Dexter TM. Growth and development of haemopoietic cells: a deterministic process? Haematol Blood Transfus. 1989;32:172-177.
30. Becker M, Sommer A, Kratzschmar JR, Seidel H, Pohlenz HD, Fichtner I. Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther. 2005;4:151-168.
31. McElwaine S, Mulligan C, Groet J, et al. Microarray transcript profiling distinguishes the transient from the acute type of megakaryoblastic leukaemia (M7) in Down's syndrome, revealing PRAME as a specific discriminating marker. Br J Haematol. 2004;125:729-742.
32. Lightfoot J, Hitzler JK, Zipursky A, Albert M, Macgregor PF. Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome. Leukemia. 2004;18:1617-16234.